Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16.

Autor: Schoentgen N; CHU Brest, Service Urologie, Brest, France., Marolleau J; CHU Brest, Service Urologie, Brest, France.; Université de Brest, Faculté de Médecine et des Sciences de la Santé, Brest, France.; Université Bretagne Loire, Rennes, France., Delage F; CHU Brest, Service Urologie, Brest, France., Coquet JB; CHU Brest, Service Urologie, Brest, France., Fourcade A; CHU Brest, Service Urologie, Brest, France.; Université de Brest, Faculté de Médecine et des Sciences de la Santé, Brest, France.; Université Bretagne Loire, Rennes, France., Callerot P; CHU Brest, Service Urologie, Brest, France., Serey-Eiffel S; CHU Brest, Service Urologie, Brest, France., Malhaire JP; CHU Brest, Service de Radiothérapie, Brest, France., Pradier O; Université de Brest, Faculté de Médecine et des Sciences de la Santé, Brest, France.; Université Bretagne Loire, Rennes, France.; CHU Brest, Service de Radiothérapie, Brest, France.; LaTIM, INSERM, UMR 1101, Univ Brest, Brest, France., Schick U; Université de Brest, Faculté de Médecine et des Sciences de la Santé, Brest, France.; Université Bretagne Loire, Rennes, France.; CHU Brest, Service de Radiothérapie, Brest, France.; LaTIM, INSERM, UMR 1101, Univ Brest, Brest, France., Fournier G; CHU Brest, Service Urologie, Brest, France.; Université de Brest, Faculté de Médecine et des Sciences de la Santé, Brest, France.; Université Bretagne Loire, Rennes, France.; LaTIM, INSERM, UMR 1101, Univ Brest, Brest, France.; CeRePP, Paris, France., Valeri A; CHU Brest, Service Urologie, Brest, France.; Université de Brest, Faculté de Médecine et des Sciences de la Santé, Brest, France.; Université Bretagne Loire, Rennes, France.; LaTIM, INSERM, UMR 1101, Univ Brest, Brest, France.; CeRePP, Paris, France.
Jazyk: angličtina
Zdroj: Journal of contemporary brachytherapy [J Contemp Brachytherapy] 2019 Jun; Vol. 11 (3), pp. 195-200. Date of Electronic Publication: 2019 Jun 28.
DOI: 10.5114/jcb.2019.85793
Abstrakt: Purpose: Prostate brachytherapy (BT) is a validated treatment for localized prostate cancer (CaP) and an attractive therapy option for patients seeking to preserve erectile function (EF). The aim of this paper is to prospectively assess EF evolution during 4 years after BT.
Material and Methods: Between February 2007 and July 2012, 179 patients underwent an exclusive Iodine-125 BT, for low-intermediate favorable risk CaP of whom, 102 had an initial international index of erectile function 5 score (IIEF-5) > 16 and were included in the study. Of those, 12.7% received neo-adjuvant hormonotherapy (HT) to decrease the prostate volume. Post-BT intake of phosphodiesterase inhibitors (PDE5i) was not an exclusion criterion. Erectile function was prospectively assessed using a validated questionnaire IIEF-5 before treatment and annually for 4 years.
Results: At 1-year follow-up, 54% of patients preserved an IIEF-5 > 16 and only 8% suffered from severe ED. During the next 3 years, the results were not statistically different. The mean IIEF-5 lost 4 points during the first year, 17 vs. 21, and remained stable during the following 3 years. We did not find any significant differences in the proportion of patients treated by PDE5i (18-20%). As for patients with a normal preoperative IIEF-5 (> 21) ( n = 52), 35-42% preserved a normal EF and 71-77% maintained an IIEF-5 > 16, including 13-19% of patients who needed PDE5i. Those results were stable for over 4 years.
Conclusions: During the first 4 years after BT, more than half of patients maintained an IIEF-5 > 16, and EF results remained stable. Severe erectile dysfunction (ED) was very rare.
Competing Interests: Authors report no conflict of interest.
Databáze: MEDLINE
Externí odkaz: